Epigenomics Company Top Insiders

EPGNF Stock  USD 0.79  0.00  0.00%   
Epigenomics employs about 36 people. The company is managed by 5 executives with a total tenure of roughly 23 years, averaging almost 4.0 years of service per executive, having 7.2 employees per reported executive. Examination of Epigenomics' management performance can provide insight into the company performance.
Gregory Hamilton  CEO
CEO Board
Noel Doheny  CEO
CEO of Epigenomics Inc.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Epigenomics Management Team Effectiveness

The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.
100%

Epigenomics Workforce Comparison

Epigenomics AG is one of the top stocks in number of employees category among its peers. The total workforce of Diagnostics & Research industry is currently estimated at about 57,523. Epigenomics adds roughly 36.0 in number of employees claiming only tiny portion of equities under Diagnostics & Research industry.
JavaScript chart by amCharts 3.21.15OthersNTRAQGENILMNSYNHEPGNF

Epigenomics AG Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Epigenomics AG Price Series Summation is a cross summation of Epigenomics price series and its benchmark/peer.
JavaScript chart by amCharts 3.21.15Dec2025FebJan 27FebFeb 10Feb 17Feb 24Mar0.7850.7900.795 0.20.40.60.81.0 1.401.451.501.551.601.65 0.7850.7900.795 Show all
JavaScript chart by amCharts 3.21.15Epigenomics AG Volume Epigenomics AG Closing Prices Sotera Health Closing Prices - Benchmark Epigenomics AG Price Series Summation

Epigenomics Notable Stakeholders

An Epigenomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Epigenomics often face trade-offs trying to please all of them. Epigenomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Epigenomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gregory HamiltonCEO BoardProfile
Noel DohenyCEO of Epigenomics Inc.Profile
Frederic HilkeInvestor OfficerProfile
Jens RavensCFO BoardProfile
Andrew LukowiakPres OfficerProfile

About Epigenomics Management Performance

The success or failure of an entity such as Epigenomics AG often depends on how effective the management is. Epigenomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Epigenomics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Epigenomics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.

Epigenomics Workforce Analysis

Traditionally, organizations such as Epigenomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Epigenomics within its industry.

Epigenomics Manpower Efficiency

Return on Epigenomics Manpower

Revenue Per Employee172.3K
Revenue Per Executive1.2M
Net Loss Per Employee67.4K
Net Loss Per Executive485.6K
Working Capital Per Employee138.9K
Working Capital Per Executive1000K

Complementary Tools for Epigenomics Pink Sheet analysis

When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios